Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM TSE:CUS NASDAQ:MDNA TSE:VBV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$9.25+6.9%$9.09$0.06▼$14.93$7.07M0.98557,110 shs8,587 shsCUSChemtrade Electrochem Inc,C$0.00C$1.18▼C$1.65C$306.50MN/A271,090 shs13,269 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsVBVVBI VaccinesC$0.00C$3.85▼C$7.60C$308.86MN/A3,637 shs1,300 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+6.87%+0.83%+11.45%+1.20%-78.08%CUSChemtrade Electrochem Inc,0.00%0.00%0.00%0.00%0.00%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%VBVVBI Vaccines0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.6659 of 5 stars3.50.00.00.03.20.00.0CUSChemtrade Electrochem Inc,N/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVBVVBI VaccinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.002,872.97% UpsideCUSChemtrade Electrochem Inc, 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideVBVVBI Vaccines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K48.40N/AN/A$0.20 per share46.25CUSChemtrade Electrochem Inc,N/AN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AVBVVBI VaccinesC$3.36M0.00N/AN/AC$1.01 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACUSChemtrade Electrochem Inc,N/AN/A0.00N/AN/AN/AN/AN/AN/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/AVBVVBI VaccinesN/A-C$0.97N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACUSChemtrade Electrochem Inc,C$0.022.44%N/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AVBVVBI VaccinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CUSChemtrade Electrochem Inc,N/AN/AN/AMDNAMedicenna TherapeuticsN/A9.579.57VBVVBI Vaccines14.292.642.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CUSChemtrade Electrochem Inc,N/AMDNAMedicenna Therapeutics12.38%VBVVBI VaccinesN/AInsider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CUSChemtrade Electrochem Inc,N/AMDNAMedicenna Therapeutics33.10%VBVVBI VaccinesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableCUSChemtrade Electrochem Inc,60186.89 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableVBVVBI Vaccines2264.08 millionN/ANot OptionableMDNA, VBV, CUS, and AIM HeadlinesRecent News About These CompaniesDecades of research push cytomegalovirus vaccine closer to realityJanuary 7, 2025 | msn.comFive Covid-19 vaccine false theories - debunkedOctober 26, 2024 | bbc.co.ukVBIVQ VBI Vaccines Inc.August 15, 2024 | seekingalpha.comVBI Vaccines Inc. (Nasdaq: VBIV) Rises from the Ashes and is NASDAQ Top Percentage GainerAugust 6, 2024 | investorideas.comIVBI Vaccines Starts Restructuring Procedure in CanadaJuly 30, 2024 | marketwatch.comVBI Vaccines secures court protection as it restructures, seeks buyer(s)July 30, 2024 | fiercebiotech.comFVBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023April 16, 2024 | msn.comVBI Vaccines sells hepatitis B vaccine candidate, manufacturing digs to partner Brii Biosciences for up to $33 millionFebruary 14, 2024 | fiercepharma.comFThe Truth About VaccinesJanuary 6, 2024 | webmd.comWVBI Vaccines Inc VBIVOctober 31, 2023 | morningstar.comMAccess to new Covid-19 vaccines delayed for Vermonters on MedicaidSeptember 27, 2023 | vtdigger.orgVNo, Pfizer COVID-19 vaccine doesn't cause 'VAIDS.' That's not a real condition | Fact checkSeptember 26, 2023 | usatoday.comAvailability of new 2023–2024 COVID-19 vaccine in VirginiaSeptember 26, 2023 | newsleader.comNThe Consumer’s Guide to RSV Vaccines for Older AdultsSeptember 24, 2023 | everydayhealth.comEUpdated COVID-19 vaccine recommended for everyone; old, young, immunocompromised will benefit mostSeptember 23, 2023 | usatoday.comIs It Safe to Get Multiple Vaccines at the Same Time?September 22, 2023 | everydayhealth.comEThe real data behind the new COVID vaccines the White House is pushingSeptember 21, 2023 | nypost.comNNew COVID vaccines will be available in RI. Here's how to get one.September 20, 2023 | providencejournal.comPCOVID vaccine pill that kills virus before it infects the body could be comingSeptember 15, 2023 | nypost.comNInterim results show Brii’s therapeutic HBV vaccine induces immune responseSeptember 8, 2023 | bioworld.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Catalysts Driving Plug Power’s Turnaround CaseBy Jeffrey Neal Johnson | July 18, 2025View 3 Catalysts Driving Plug Power’s Turnaround CaseAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes Investors3 Stocks to Cushion Your Portfolio This Earnings SeasonBy Chris Markoch | July 16, 2025View 3 Stocks to Cushion Your Portfolio This Earnings SeasonSnag These 3 Bargain Tech Stocks Before They PopBy Gabriel Osorio-Mazilli | June 27, 2025View Snag These 3 Bargain Tech Stocks Before They PopThis Fund Manager Says You Should Get Out of Tesla and Apple—NowBy Brian O'Connell | July 16, 2025View This Fund Manager Says You Should Get Out of Tesla and Apple—NowMDNA, VBV, CUS, and AIM Company DescriptionsAIM ImmunoTech NYSE:AIM$9.25 +0.60 (+6.94%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$9.21 -0.04 (-0.44%) As of 07/18/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Chemtrade Electrochem Inc, TSE:CUSChemtrade Electrochem Inc, formerly Canexus Corp is a Canada-based company engaged in operating North American sodium chlorate production facilities; a North American chlor-alkali production facility and a sodium chlorate and chlor-alkali production facility. Its segments are North America Sodium Chlorate, North America Chlor-alkali (NACA) and South America (sodium chlorate and chlor-alkali). The North America Sodium Chlorate segment sells sodium chlorate to the South America segment and provides transloading services to the NACA segment for caustic soda transloaded from barges into trucks for delivery to NACA customers. It produces sodium chlorate in Beauharnois, Quebec; Brandon, Manitoba, and Nanaimo, British Columbia; chlor-alkali products (caustic soda, chlorine, and hydrochloric acid) in North Vancouver, British Columbia, and sodium chlorate and chlor-alkali products in Espirito Santo, Brazil. It caters its production to the pulp and paper, water treatment and oil and gas sectors.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.VBI Vaccines TSE:VBVVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
